China

WHO Admits It Was Never Told About COVID By China, Instead Found Out From U.S. Data

Published

3 years ago

July 2, 2020

Despite earlier claims and countless defenses made by World Health Organization officials, an updated timeline by the international health body shows China never self-reported the COVID-19 outbreak that led to drastic economic and health consequences across the world.

A quiet change to a timeline of COVID events in late June shows what many mainstream media outlets and government officials have denied for months: China didn’t inform the WHO about the outbreak. Instead, on December 31, “a translation of a Chinese media report about the outbreak is posted to ProMED, a U.S.-based open-access platform for early intelligence about infectious disease outbreaks,” according to a U.S. Naval Institute report.

The first inklings of the impending pandemic, and the first time the WHO heard about it, came from this U.S. report — the WHO then sent officials to investigate its validity in China the next day.

This runs contrary to a previous version of the timeline that falsely claimed on December 31: “Wuhan Municipal Health Commission, China, reported a cluster of cases of pneumonia in Wuhan, Hubei Province. A novel coronavirus was eventually identified.” This did not happen.

Rather, the updated June 30 truthful version now says that on December 31 the WHO “picked up a media report on ProMED” about the mysterious cluster of pneumonia cases in Wuhan. The new timeline admits that ProMED is run by the International Society for Infectious Diseases — a U.S. based organization headquartered in Brookline, Massachusetts.

The now-eerie Dec. 31 ProMED report says, “It is understood that the 1st patient with unexplained pneumonia that appeared in Wuhan this time came from Wuhan South China Seafood Market.”

This newly admitted information disrupts the countless defenses given by Chinese officials and allies at the WHO.

A June 4 article by China Daily said there “is no legal basis” for faulting China for the spread of the virus.

“What we’ve done is strictly obey the international rules and fulfill our international obligations,” Huang Jin, a law professor specializing in international law at China University of Political Science and Law in Beijing falsely said in the propaganda article. “For example, we took the initiative to evaluate the pandemic situation and reported it in a timely fashion to the World Health Organization as well as other countries and regions, and we also accepted inspections from the WHO.”

Now that it’s admitted China didn’t report in a timely fashion, but rather the U.S. did, the Chinese have dropped this false talking point, as reported by the Free Beacon.

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

2 days ago

June 7, 2023

Sara Carter Staff

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4

— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.